Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF EQUITY

v3.20.1
CONSOLIDATED STATEMENTS OF EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Treasury
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Beginning balance, shares (in shares) at Dec. 31, 2018   586,881,720 549,907      
Beginning balance at Dec. 31, 2018 $ 1,791,291 $ 5,869 $ (1,791) $ 3,004,422 $ (20,131) $ (1,197,078)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Equity-based compensation expense 4,457     4,457    
Exercise of Common Stock options and warrants, shares (in shares)   19,232        
Exercise of Common Stock options and warrants (3)     (3)    
2025 convertible notes including share lending arrangement (in shares)   29,250,000        
2025 convertible notes including share lending arrangement 50,852 $ 293   50,559    
Net loss (80,762)         (80,762)
Other comprehensive loss (3,098)       (3,098)  
Ending balance, shares (in shares) at Mar. 31, 2019   616,150,952 549,907      
Ending balance at Mar. 31, 2019 1,762,737 $ 6,162 $ (1,791) 3,058,509 (23,229) (1,276,914)
Beginning balance, shares (in shares) at Dec. 31, 2019   670,378,701 549,907      
Beginning balance at Dec. 31, 2019 1,614,759 $ 6,704 $ (1,791) 3,142,993 (22,070) (1,511,077)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Equity-based compensation expense 2,451     2,451    
Exercise of Common Stock options and warrants 0          
2025 convertible notes including share lending arrangement 0          
Net loss (59,132)         (59,132)
Other comprehensive loss (8,117)       (8,117)  
Ending balance, shares (in shares) at Mar. 31, 2020   670,378,701 549,907      
Ending balance at Mar. 31, 2020 $ 1,548,619 $ 6,704 $ (1,791) $ 3,145,444 $ (30,187) $ (1,571,551)